Putting Carevive SMART Data to Work

Carevive SMART Data is making waves in the pharmaceutical industry as it gets licensed to companies looking to enhance their value chain. This revolutionary dataset is being utilized for crucial use cases, particularly in clinical trials.

Pharmaceutical companies are now leveraging SMART Data to precisely target the right patient populations and determine essential patient experience measures for inclusion in their clinical trials. By integrating this definitive set of Patient-Reported Outcomes (PROs) into new study designs, trials gain a valuable dimension that bolsters the quality of trial data and strengthens regulatory submissions.

We’re excited to discuss Carevive SMART Data with you in-depth, showcasing how it can transform your clinical trials and regulatory strategies. Together, let’s pave the way for more effective and patient-centered therapies in the ever-evolving landscape of cancer care.

Recent Episodes

In this impactful episode of the ConCensis podcast, host Yasmeen Hassan sits down with Robby Miller, Sterile Processing Manager at St. Joseph’s Hospital Medical Center, to explore how artificial intelligence is revolutionizing the field of sterile processing. With nearly 30 years of experience in healthcare, Miller shares his journey from EMT to SPD leader, offering…

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

In an era where precision and predictability define the future of oncology, organoid technology is emerging as a transformative tool in drug discovery. These miniature, lab-grown 3D tissues mirror real human biology more closely than traditional 2D models or even animal systems, offering researchers the potential to predict patient-specific drug responses. As organoids become more…